港股上市公司康哲药业近日发布公告,将附属公司德镁医药股份分拆并于联交所主板独立上市。德镁医药主要负责康哲药业在国内的皮肤健康业务,最近三年均处亏损状态。 目前,德镁医药已向联交所递交申请,康哲药业表示,分拆预计将通过由康哲药业以实物方式向股东分派其持有的所有德镁医药股份的方式实施。 德镁医药为康哲药业附属公司,德镁医药90.8%权益由康哲药业实益拥有。作为一家聚焦皮肤健康的创新型医药企业,德镁...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.